title: [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder].
abstract: A 45-year-old patient with a medication-resistant obsessive-compulsive disorder was treated successfully by topiramate augmentation. Obsessive-compulsive disorder is associated neurobiologically with overactivation of the cortico-striato-thalamo-cortical circuit. Because the neurotransmitter glutamate plays an important role in this circuit, medication that has glutamate antagonism, such as the antiepileptic drug topiramate, may reduce the symptoms of obsessive-compulsive disorder. Further study is needed to find out whether topiramate augmentation is more effective than placebos in patients with a medication-resistant obsessive-compulsive disorder.
authors.affiliation: Leids Universitair Medisch Centrum, afdeling Psychiatrie, Postbus 9600, 2300 RC Leiden. d.j.vinkers@lumc.nl
authors.forename: D J
authors.initials: DJ
authors.lastname: Vinkers
authors.forename: N J A
authors.initials: NJ
authors.lastname: van der Wee
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D004351:Drug Resistance; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D018691:Excitatory Amino Acid Antagonists; D000077236:Topiramate; D005632:Fructose; D018698:Glutamic Acid